Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First in Human, Phase 1 Safety Study in Two Parts to Determine the Safety, Tolerability and Anti-cancer Immune-modulatory Effects of MRx0518 in Patients With Solid Tumour Awaiting Surgical Removal of the Tumour.

NCT03934827 is registered in ClinicalTrials.gov with Imperial College London as lead sponsor.

NCT NCT03934827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03934827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First in Human, Phase 1 Safety Study in Two Parts to Determine the Safety, Tolerability and Anti-cancer Immune-modulatory Effects of MRx0518 in Patients With Solid Tumour Awaiting Surgical Removal of the Tumour.
Lead sponsor
Imperial College London
Phase
Phase 1
Overall status
Unknown status
Start date
April 10, 2019
Completion date
December 31, 2022
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, breast cancer, head and neck cancer, lung cancer, melanoma, ovarian cancer, prostate cancer, renal cancer, urethral cancer, uterine cancer